Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review
Journal
Clinical Infectious Diseases
ISSN
1058-4838
1537-6591
Date Issued
2023
Author(s)
Sarah B Doernberg
Cesar A Arias
Deena R Altman
Ahmed Babiker
Helen W Boucher
C Buddy Creech
Sara E Cosgrove
Scott R Evans
Vance G Fowler
Stephanie A Fritz
Toshimitsu Hamasaki
Brendan J Kelly
Sixto M Leal
Catherine Liu
Thomas P Lodise
Loren G Miller
Barbara E Murray
Melinda M Pettigrew
Felicia Ruffin
Marc H Scheetz
Bo Shopsin
Truc T Tran
Nicholas A Turner
Derek J Williams
Smitha Zaharoff
Thomas L Holland
Robin Patel
Heather King
Tori Kinamon
Weixiao Dai
Holly Geres
Nancie Deckard
Carl Schuler
Ivra Bunn
Shrabani Sharma
Cathy Wickward
Jason Waller
Holly Wilson
Maureen Mehigan
Varduhi Ghazaryan
Erica Raterman
Tamika Samuel
Marina Lee
Type
Resource Types::text::journal::journal article
URL Institutional Repository
Abstract
<jats:title>Abstract</jats:title><jats:p>The Antibacterial Resistance Leadership Group (ARLG) has prioritized infections caused by gram-positive bacteria as one of its core areas of emphasis. The ARLG Gram-positive Committee has focused on studies responding to 3 main identified research priorities: (1) investigation of strategies or therapies for infections predominantly caused by gram-positive bacteria, (2) evaluation of the efficacy of novel agents for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci, and (3) optimization of dosing and duration of antimicrobial agents for gram-positive infections. Herein, we summarize ARLG accomplishments in gram-positive bacterial infection research, including studies aiming to (1) inform optimal vancomycin dosing, (2) determine the role of dalbavancin in MRSA bloodstream infection, (3) characterize enterococcal bloodstream infections, (4) demonstrate the benefits of short-course therapy for pediatric community-acquired pneumonia, (5) develop quality of life measures for use in clinical trials, and (6) advance understanding of the microbiome. Future studies will incorporate innovative methodologies with a focus on interventional clinical trials that have the potential to change clinical practice for difficult-to-treat infections, such as MRSA bloodstream infections.</jats:p>
Cite this document
Doernberg, S. B., Arias, C. A., Altman, D. R., Babiker, A., Boucher, H. W., Creech, C. B., Cosgrove, S. E., Evans, S. R., Fowler, V. G., Fritz, S. A., Hamasaki, T., Kelly, B. J., Leal, S. M., Liu, C., Lodise, T. P., Miller, L. G., Munita, J. M., Murray, B. E., Pettigrew, M. M., … Lee, M. (2023). Priorities and progress in gram-positive bacterial infection research by the antibacterial resistance leadership group: A narrative review. Clinical Infectious Diseases, 77(Supplement_4), S295-S304. https://doi.org/10.1093/cid/ciad565
Subjects
antibacterial agents
;
antibacterial resistance
;
gram-positive bacterial infections
;
methicillin-resistant staphylococcus aureus
;
vancomycin-resistant enterococci
;
anti-bacterial agents
;
child
;
gram-positive bacteria
;
gram-positive bacterial infections
;
humans
;
leadership
;
methicillin-resistant staphylococcus aureus
;
quality of life
;
sepsis
;
antibiotic agent
;
dalbavancin
;
vancomycin
;
antiinfective agent
;
antibiotic resistance
;
antibiotic therapy
;
article
;
bacterium detection
;
bloodstream infection
;
clinical trial (topic)
;
clostridioides difficile
;
community acquired pneumonia
;
enterococcal infection
;
fecal microbiota transplantation
;
gram positive infection
;
human
;
methicillin resistant staphylococcus aureus
;
methicillin resistant staphylococcus aureus infection
;
nonhuman
;
outpatient care
;
pharmacodynamics
;
quality of life
;
short course therapy
;
treatment duration
;
unmet medical need
;
vancomycin-resistant enterococcus infection
;
child
;
gram positive bacterium
;
gram positive infection
;
leadership
;
methicillin resistant staphylococcus aureus
;
microbiology
;
sepsis